Skip to content

A randomized, double-blind, placebo-controlled clinical trial of Shufeng Zhike Mixture in the treatment of post-infectious cough (fengxie loves the lung syndrome)

A randomized, double-blind, placebo-controlled clinical trial of Shufeng Zhike Mixture in the treatment of post-infectious cough (fengxie loves the lung syndrome)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100048649
Enrollment
Unknown
Registered
2021-07-12
Start date
2021-10-01
Completion date
Unknown
Last updated
2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cough after the infection

Interventions

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of Western medicine for post-infection cough; 2. In line with the diagnostic criteria of Chinese medicine for cough, wind and pathogenic love of the lung syndrome; 3. Cough severity score >=40; 4. Cough duration 3-8 weeks; 5. Age 18-65 years old; 6. Informed consent and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with cough variant asthma, upper airway cough syndrome, eosinophilic bronchitis, gastroesophageal reflux cough, chronic bronchitis and other causes of cough; 2. Patients with severe pulmonary diseases (such as chronic obstructive pulmonary disease, lung cancer, tuberculosis); 3. Patients who have taken angiotensin-converting enzyme inhibitors within the past 2 months; 4. Patients with abnormal behavior or mental illness; 5. Patients who smoke or quit smoking for less than three months; 6. Combined with serious primary diseases of cardiovascular and cerebrovascular, liver, kidney and hematopoietic system, or serious diseases affecting their survival, such as tumor or AIDS; or mentally or legally disabled patients; 7. ALT>1.5 times normal upper limit of reference value, and/or serum creatinine > upper limit of normal reference value; 8. White blood cells 10.0x10^9/L, and/or neutrophil classification>80%; 9. Patients who have taken drugs similar to those of the experimental drug in the past 1 month; 10. Women who are pregnant or planning to become pregnant, women who are breastfeeding; those with allergic constitution or known ingredients of the drug; those who have participated in clinical trials of other drugs in the past 3 months.

Design outcomes

Primary

MeasureTime frame
cough disappearance rate;

Secondary

MeasureTime frame
cough relief rate;cough recurrence rate;changes in cough symptoms point;cough disappearance time;

Countries

China

Contacts

Public ContactLiu Wei

West China Hospital of Sichuan University

593988845@qq.com+86 18583678610

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026